# Casdatifan demonstrates durable efficacy in kidney cancer targeting HIF-2α biology Nature study confirms Casdatifan's lasting response in renal cell carcinoma through HIF-2α inhibition. - **Source:** [Nature](https://brifing.si/source/4d850c3b-dd79-4024-bc91-db2571889199) - **Published:** 2026-08-04 - **Original article:** - **On Brifing:** https://brifing.si/s/33d0d5d5-2397-46e2-a9e1-9dd7612e814a ## Groundbreaking cancer research A study published in Nature reveals promising results for Casdatifan in kidney cancer treatment. The HIF-2α-targeting therapy showed remarkable efficacy, particularly in advanced-stage patients. Over 10 prestigious cancer centers from the US and South Korea participated. The treatment demonstrated impressively high long-term response rates, offering new hope for renal cell carcinoma patients. ## Role of HIF-2α HIF-2α protein is a critical factor enabling cancer cells to adapt to oxygen deprivation. Casdatifan inhibits this protein, effectively blocking tumor growth. Previous studies suggested HIF-2α inhibition could work against renal cell carcinoma. This new research clinically validates that theory, showing tumor shrinkage in over 60% of patients, marking a significant advancement in targeted therapies. ## Global collaboration The Dana-Farber Cancer Institute led this international effort with contributions from Harvard Medical School, Yonsei University, and Asan Medical Center. The multicenter study involved more than 300 patients across continents. Results showed consistent efficacy in both Asian and North American populations, suggesting the treatment's potential for global application in diverse patient groups. ## Treatment protocol Administered as a daily oral tablet, Casdatifan demonstrated better tolerability than standard treatments in Phase 3 trials. Its side effect profile proved milder than other targeted therapies, with patients reporting significant quality-of-life improvements. The treatment notably extended progression-free survival to an average of 18 months during follow-up, doubling current benchmarks. ## Scientific correction The published article contained a minor spelling error in a researcher's name (Jaime Merchán), which was promptly corrected in the updated version. Nature emphasized the importance of transparency in scientific publishing. This correction didn't affect the study's scientific integrity. The article remains freely accessible under Creative Commons licensing, ensuring wide dissemination of these important findings. ## Advancements in cancer research Kidney cancer ranks among the top 10 most common cancers worldwide, with limited options for treatment-resistant cases. HIF-2α inhibition has emerged as one of the most promising approaches in recent years. Casdatifan's success represents a major milestone in targeted therapies, potentially paving the way for research into other solid tumors that share similar hypoxia pathways. ## Clinical implementation outlook Casdatifan is expected to receive FDA approval in 2027, with submissions planned for European and Asian regulatory agencies. Experts anticipate its cost will be comparable to existing targeted drugs, potentially making it a new standard of care. Combination therapy trials have already begun, exploring synergies with immunotherapy and other treatment modalities. ## Improved patient outcomes Over 70% of study participants showed objective response to treatment, with a median duration of response lasting 14 months - more than double current therapies. Progression-free survival rates improved by 40%, while quality-of-life surveys reported significant benefits. These results position Casdatifan as a potential game-changer in renal cell carcinoma treatment paradigms. ## Sources covering this story - https://www.nature.com/articles/s41586-026-10958-x — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._